Correlation Between Lipocine and Uzabase
Can any of the company-specific risk be diversified away by investing in both Lipocine and Uzabase at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lipocine and Uzabase into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lipocine and Uzabase, you can compare the effects of market volatilities on Lipocine and Uzabase and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lipocine with a short position of Uzabase. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lipocine and Uzabase.
Diversification Opportunities for Lipocine and Uzabase
Pay attention - limited upside
The 3 months correlation between Lipocine and Uzabase is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Lipocine and Uzabase in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Uzabase and Lipocine is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lipocine are associated (or correlated) with Uzabase. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Uzabase has no effect on the direction of Lipocine i.e., Lipocine and Uzabase go up and down completely randomly.
Pair Corralation between Lipocine and Uzabase
If you would invest 1,105 in Uzabase on September 4, 2024 and sell it today you would earn a total of 0.00 from holding Uzabase or generate 0.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 4.76% |
Values | Daily Returns |
Lipocine vs. Uzabase
Performance |
Timeline |
Lipocine |
Uzabase |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Lipocine and Uzabase Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Lipocine and Uzabase
The main advantage of trading using opposite Lipocine and Uzabase positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lipocine position performs unexpectedly, Uzabase can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Uzabase will offset losses from the drop in Uzabase's long position.Lipocine vs. Reviva Pharmaceuticals Holdings | Lipocine vs. ZyVersa Therapeutics | Lipocine vs. Unicycive Therapeutics | Lipocine vs. Checkpoint Therapeutics |
Uzabase vs. Apogee Therapeutics, Common | Uzabase vs. Sellas Life Sciences | Uzabase vs. Lipocine | Uzabase vs. United Rentals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Complementary Tools
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |